Cargando…

The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies

Hypercholesterolemia is a clinically relevant condition with an ascertained role in atherogenesis. In particular, its presence directly correlates to the risk of atherosclerotic cardiovascular disease (ASCVD). As known, cardiovascular diseases pose a significant economic burden worldwide; however, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrara, Pietro, Di Laura, Danilo, Cortesi, Paolo A., Mantovani, Lorenzo G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274865/
https://www.ncbi.nlm.nih.gov/pubmed/34252164
http://dx.doi.org/10.1371/journal.pone.0254631
_version_ 1783721619272761344
author Ferrara, Pietro
Di Laura, Danilo
Cortesi, Paolo A.
Mantovani, Lorenzo G.
author_facet Ferrara, Pietro
Di Laura, Danilo
Cortesi, Paolo A.
Mantovani, Lorenzo G.
author_sort Ferrara, Pietro
collection PubMed
description Hypercholesterolemia is a clinically relevant condition with an ascertained role in atherogenesis. In particular, its presence directly correlates to the risk of atherosclerotic cardiovascular disease (ASCVD). As known, cardiovascular diseases pose a significant economic burden worldwide; however, a clear picture of the economic impact of ASCVD secondary to hypercholesterolemia is lacking. This study aiming at conducting a systematic review of the current literature to assess the economic impact of familial hypercholesterolemia (FH), non-familial hypercholesterolemia (non-FH) or mixed dyslipidemia. A literature search was performed in Medline/PubMed and Embase database up to September 1(st), 2020, exploring evidence published from 2010. The literature review was conducted in accordance with PRISMA guidelines. To be included the studies must be conducted on people who have been diagnosed with familial hypercholesterolemia, non-familial hypercholesterolemia or mixed dyslipidemia, and report data/information on costs attributable to these conditions and their sequelae. A total of 1260 studies were retrieved. After reading the titles and abstract, 103 studies were selected for full reading and eight met the criteria for inclusion. All but one studies were published in the American continent, with the majority conducted in US. An observational design with a prevalence approach were used and all estimated the economic burden of CVD. Direct cost estimates as annual average health expenditure on all population, ranging from $17 to $259 million. Few studies assessing the economic impact of hypercholesterolemia are available in the literature and new researches are needed to provide a more updated and reliable picture. Despite this scarceness of evidence, this review adds important data for future discussion on the knowledge of the economic impact of hypercholesterolemia and costs of care associated to this condition, with important implication for public health researches and novel therapies implementation.
format Online
Article
Text
id pubmed-8274865
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-82748652021-07-27 The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies Ferrara, Pietro Di Laura, Danilo Cortesi, Paolo A. Mantovani, Lorenzo G. PLoS One Research Article Hypercholesterolemia is a clinically relevant condition with an ascertained role in atherogenesis. In particular, its presence directly correlates to the risk of atherosclerotic cardiovascular disease (ASCVD). As known, cardiovascular diseases pose a significant economic burden worldwide; however, a clear picture of the economic impact of ASCVD secondary to hypercholesterolemia is lacking. This study aiming at conducting a systematic review of the current literature to assess the economic impact of familial hypercholesterolemia (FH), non-familial hypercholesterolemia (non-FH) or mixed dyslipidemia. A literature search was performed in Medline/PubMed and Embase database up to September 1(st), 2020, exploring evidence published from 2010. The literature review was conducted in accordance with PRISMA guidelines. To be included the studies must be conducted on people who have been diagnosed with familial hypercholesterolemia, non-familial hypercholesterolemia or mixed dyslipidemia, and report data/information on costs attributable to these conditions and their sequelae. A total of 1260 studies were retrieved. After reading the titles and abstract, 103 studies were selected for full reading and eight met the criteria for inclusion. All but one studies were published in the American continent, with the majority conducted in US. An observational design with a prevalence approach were used and all estimated the economic burden of CVD. Direct cost estimates as annual average health expenditure on all population, ranging from $17 to $259 million. Few studies assessing the economic impact of hypercholesterolemia are available in the literature and new researches are needed to provide a more updated and reliable picture. Despite this scarceness of evidence, this review adds important data for future discussion on the knowledge of the economic impact of hypercholesterolemia and costs of care associated to this condition, with important implication for public health researches and novel therapies implementation. Public Library of Science 2021-07-12 /pmc/articles/PMC8274865/ /pubmed/34252164 http://dx.doi.org/10.1371/journal.pone.0254631 Text en © 2021 Ferrara et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ferrara, Pietro
Di Laura, Danilo
Cortesi, Paolo A.
Mantovani, Lorenzo G.
The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies
title The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies
title_full The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies
title_fullStr The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies
title_full_unstemmed The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies
title_short The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies
title_sort economic impact of hypercholesterolemia and mixed dyslipidemia: a systematic review of cost of illness studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274865/
https://www.ncbi.nlm.nih.gov/pubmed/34252164
http://dx.doi.org/10.1371/journal.pone.0254631
work_keys_str_mv AT ferrarapietro theeconomicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies
AT dilauradanilo theeconomicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies
AT cortesipaoloa theeconomicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies
AT mantovanilorenzog theeconomicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies
AT ferrarapietro economicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies
AT dilauradanilo economicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies
AT cortesipaoloa economicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies
AT mantovanilorenzog economicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies